Zenas BioPharma, Bicara Therapeutics sets IPO price ranges as summer lull ends
MarketWatchZenas BioPharma Inc. and Bicara Therapeutics Inc. on Friday both set estimated price ranges in their initial public offerings in a sign that the traditional summer lull in deals is coming to an end.